Associated Papers
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
40359938 (PubMed )
Supplement: mmc6.xlsx › Sheet_1
Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine.
Zhou Y et al.
Science Advances, 2021
34516913 (PubMed )
Supplement: sciadv.abi6856_tables_s1_to_s8.zip › sciadv.abi6856_Table_S4.xlsx › Sheet1
Genomic profile of advanced breast cancer in circulating tumour DNA.
Kingston B et al.
Nature Communications, 2021
33893289 (PubMed )
Supplement: 41467_2021_22605_MOESM4_ESM.xlsx › SNVs_Indels
Spatially interacting phosphorylation sites and mutations in cancer.
Huang KL et al.
Nature Communications, 2021
33875650 (PubMed )
Supplement: 41467_2021_22481_MOESM4_ESM.xlsx › TableS5.ActMutationClusters
Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel.
Froyen G et al.
Cancers, 2019
Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance.
Stetson D et al.
Jco Precision Oncology, 2019
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.
Pejerrey SM et al.
Hormones & Cancer, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
30053901 (PubMed )
Supplement: 13073_2018_564_MOESM2_ESM.xlsx › 13
The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.
Gibson WJ et al.
Nature Genetics, 2016
27348297 (PubMed )
Supplement: NIHMS791814-supplement-1.pdf
Are Estrogen Receptor Genomic Aberrations Predictive of Hormone Therapy Response in Breast Cancer?
Tabarestani S et al.
Iranian Journal of Cancer Prevention, 2016
Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients.
Niu J et al.
Oncotargets and Therapy, 2015
Random mutagenesis of human estrogen receptor ligand binding domain identifies mutations that decrease sensitivity to estradiol and increase sensitivity to a diphenol indene-ol compound: basis for a regulatable expression system.
Miller N et al.
The Journal of Steroid Biochemistry and Molecular Biology, 1998
Select a paper to view details